Citations

Mayo Clinic

Clear

16256 citation(s) found for "Ha, David R".

Mitral Annular Calcification, Aortic Valve Sclerosis, and Incident Stroke in Adults Free of Clinical Cardiovascular Disease
Wiebers, David O. , Whisnant, Jack P., Galloway, James M., Welty, Thomas K. , Lee, Elisa T. , Resnick, Helaine E. , Roman, Mary J. , Devereux, Richard B. , Kizer, Jorge R. , Best, Lyle G.

Stroke | October 28, 2005 | Volume: 36 | Issue: 12 | Pages: 2533-2537

10.1161/01.str.0000190005.09442.ad | PMID 16254219 Get It

Background and Purpose— Mitral annular calcification (MAC) and aortic valve (AV) sclerosis have each been linked to cardiovascular disease. Whether MAC and AV sclerosis are risk factors for stroke independent of other echocardiographic or laboratory predictors has not been established. We evaluated the relationship between MAC, AV sclerosis, and first stroke events in a population-based cohort. Methods— Our study cohort consisted of 2723 American Indians participating in the Strong Heart Study who were free of prevalent cardiovascular disease. Participants underwent standardized clinical, echocardiographic, and laboratory evaluation, and incident stroke was ascertained using validated methods. Results— During a median follow-up of 7 years, 86 strokes occurred. Age- and sex-adjusted incidence rates of stroke were significantly increased for MAC (rate ratio [RR], 3.12; 95% CI, 1.77 to 5.25) but not for AV sclerosis (RR, 1.15; 95% CI, 0.45 to 2.49). MAC was also associated with a reduced time to first stroke events after adjustment for clinical variables and the inflammatory markers C-reactive protein and fibrinogen (hazard ratio [HR], 2.42; 95% CI, 1.39 to 4.21) or the echocardiographic covariates left ventricular hypertrophy and left atrial enlargement (HR, 1.89; 95% CI, 1.04 to 3.41). Individuals with and without AV sclerosis showed no significant difference in stroke-free survival in unadjusted analyses ( P =0.698). Crossing of the survival curves precluded multivariable analysis using Cox models. Conclusions— In this cohort of American Indians without clinical cardiovascular disease, the presence of MAC, but not AV sclerosis, proved to be a strong risk factor for incident stroke after extensive adjustment for other predictors. Individuals exhibiting MAC may benefit from aggressive risk factor modification, but this will require further investigation.
In Vivo Temperature Mapping of Prostate during Treatment with TherMatrx TMx-2000 Device: Heat Field and MRI Determinations of Necrotic Lesions
Larson, Benjamin T., Huidobro, Christian, Acevedo, Cristián , Busel, David, Mynderses, Lance, Collins, Joseph M. , Larson, Thayne R.

Journal of Endourology | October 27, 2005 | Volume: 19 | Issue: 8 | Pages: 1021-1025

10.1089/end.2005.19.1021 | PMID 16253074 Get It

Coronary Stent Restenosis in Patients Treated With Cilostazol
Douglas, John S., Holmes, David R. , Kereiakes, Dean J. , Block, Elizabeth H., Ghazzal, Ziyad M.B., Morris, Douglas C., Liberman, Henry, Parker, Karen M. , Jurkovitz, Claudine , Murrah, Nancy , Foster, Jovonne K., Hyde, Pamela, Grines, Cindy L. , Mancini, G.B. John , Weintraub, William S.

Circulation | October 26, 2005 | Volume: 112 | Issue: 18 | Pages: 2826-2832

10.1161/circulationaha.104.530097 | PMID 16246948 Get It

Background— Restenosis after implantation of coronary artery stents remains a significant clinical problem. We undertook a randomized, double-blind, placebo-controlled trial to determine whether cilostazol, a drug that suppresses intimal proliferation, would reduce renarrowing in patients after stent implantation in native coronary arteries. Methods and Results— We assigned 705 patients who had successful coronary stent implantation to receive, in addition to aspirin, cilostazol 100 mg BID or placebo for 6 months; clopidogrel 75 mg daily was administered to all patients for 30 days. Restenosis was determined by quantitative coronary angiography at 6 months. The minimal luminal diameter at 6 months for cilostazol-treated patients was 1.77 mm for the analysis segment (stent plus 5-mm borders) compared with 1.62 mm in the placebo group ( P =0.01). Restenosis, defined as ≥50% narrowing, occurred in 22.0% of patients in the cilostazol group and in 34.5% of the placebo group ( P =0.002), a 36% relative risk reduction. Restenosis was significantly lower in cilostazol-treated diabetics (17.7% versus 37.7%, P =0.01) and in those with small vessels (23.6% versus 35.2%, P =0.02), long lesions (29.9% versus 46.6%, P =0.04), and left anterior descending coronary artery site (19.3% versus 39.8%, P =0.001). There was no difference in bleeding, rehospitalization, target-vessel revascularization, myocardial infarction, or death. Conclusions— Treatment with the drug cilostazol resulted in a significantly larger minimal luminal diameter and a significantly lower binary restenosis rate compared with placebo-treated patients. These favorable effects were apparent in patients at high risk for restenosis.
Clinical Elements that Predict Outcome after Traumatic Brain Injury: A Prospective Multicenter Recursive Partitioning (Decision-Tree) Analysis
Brown, Allen W. , Malec, James F. , McClelland, Robyn L. , Diehl, Nancy N. , Englander, Jeffrey, Cifu, David X.

Journal of Neurotrauma | October 20, 2005 | Volume: 22 | Issue: 10 | Pages: 1040-1051

10.1089/neu.2005.22.1040 | PMID 16238482 Get It

JAK2 V617F in myeloid disorders: What do we know now, and where are we headed?
Nelson, Maria, Steensma, David P. , Steensma, David P

Leukemia & Lymphoma | October 19, 2005 | Volume: 47 | Issue: 2 | Pages: 177-194

10.1080/10428190500301348 | PMID 16321848 Get It

Hearing loss simulation: A comparison of two methods
Fabry, David A., Tasell, Dianne J. Van

The Journal of the Acoustical Society of America | October 7, 2005 | Volume: 76 | Issue: S1 | Pages: S61-S61

10.1121/1.2021941 Get It

Hearing threshold configuration of the impaired ear was simulated, via two different methods, in the normal ear of each of six subjects with unilateral sensorineural hearing loss. The simulation methods were (1) frequency-specific attenuation (filtering), and (2) masking by shaped masking noise. Identification responses to 20 consonant-vowel nonsense syllables were obtained from the normal ear of each subject in both hearing loss simulation conditions, as well as from the impaired ear. Data were scored both for percent correct syllable recognition and for errors on a set of eight consonant features. Overall performance level and consonant feature error patterns appeared to be relatively independent measures of speech recognition. For three subjects, both masking and filtering successfully simulated the effects of sensorineural hearing loss on consonant feature error patterns. For the remaining subjects, one or both of the simulation schemes was inadequate. [Supported by NINCDS Grant NS-12125.]
LONG-TERM URINARY CONTINENCE RATES AFTER SIMPLE SLING INCISION FOR RELIEF OF URINARY RETENTION FOLLOWING FASCIA LATA PUBOVAGINAL SLINGS
Thiel, David D. , Pettit, Paul D. , McClellan, W. Thomas, Petrou, Steven

Journal of Urology | October 7, 2005 | Volume: 174 | Issue: 5 | Pages: 1878-1881

10.1097/01.ju.0000177493.41432.77 | PMID 16217328 Get It

Coccidioidomycosis
Galgiani, John N. , Ampel, Neil M. , Blair, Janis E. , Catanzaro, Antonino , Johnson, Royce H. , Stevens, David A. , Williams, Paul L.

Clinical Infectious Diseases | October 5, 2005 | Volume: 41 | Issue: 9 | Pages: 1217-1223

10.1086/496991 | PMID 16206093 Get It

Vascular Endothelial Growth Factor Is Required for Coronary Collateral Growth in the Rat
Toyota, Eiji, Warltier, David C., Brock, Tommy A., Ritman, Erik L., Kolz, Christopher, O’Malley, Peter, Ročić, Petra , Focardi, Marta , Chilian, William M.

Circulation | October 3, 2005 | Volume: 112 | Issue: 14 | Pages: 2108-2113

10.1161/circulationaha.104.526954 | PMID 16203926 Get It

Background— The goal of this study was to determine whether the expression of vascular endothelial growth factor (VEGF) is critical for coronary collateral growth. Previous studies have provided an association between coronary collateral growth and VEGF, but none have allowed determination of a causal role. Methods and Results— We measured coronary collateral growth in rats subjected to repetitive episodes of myocardial ischemia (RI; one 40-second occlusion every 20 minutes for 2 hours 40 minutes, followed by 5 hours 20 minutes of rest, with this 8-hour cycle repeated 3 times per day for 10 days). Collateral growth was measured from blood flow (radioactive microspheres), visualization of arterial-arterial anastomoses (x-ray micro-CT), and maintenance of function during complete coronary occlusion in 3 groups of animals: sham (received instrumentation but no RI), experimental (subjected to RI), and anti–vascular endothelial growth factor (RI+anti-VEGF 0.6 mg/100 g per day) to block the endogenous actions of VEGF. In the 3 groups, native collateral flow (measurement for RI or sham protocol) averaged 0.2 to 0.3 mL · min −1 · g −1 of tissue. In the sham group, collateral flow did not increase during the protocol. Collateral flow in the control RI group increased by ≈6-fold to 1.63 mL · min −1 · g −1 tissue, but in the anti-VEGF group, collateral flow did not increase after the RI protocol (0.22 mL · min −1 · g −1 ). In acute experiments, collateral flow was unchanged during vasodilation with dipyridamole, indicating the increases in collateral flow are due to collateral growth and not vasodilation. X-ray micro-CT analysis revealed a 3-fold increase (versus sham group) in the number of arterial-arterial anastomoses per heart after RI, which was prevented by treatment with anti-VEGF. The growth of the collateral circulation was functional in the RI group because complete coronary occlusion did not induce any untoward effects on hemodynamics or arrhythmias. In the sham or anti-VEGF groups, coronary occlusion at the end of the protocol induced many arrhythmias and deterioration of function. Conclusions— From these results, we conclude that the expression of VEGF is critical to the growth of coronary collaterals.
Age- and Gender-Related Ventricular-Vascular Stiffening
Redfield, Margaret M. , Jacobsen, Steven J. , Rodeheffer, Richard J. , Borlaug, Barry A. , Kass, David A.

Circulation | October 3, 2005 | Volume: 112 | Issue: 15 | Pages: 2254-2262

10.1161/circulationaha.105.541078 | PMID 16203909 Get It

Background— Increases in vascular (Ea), ventricular systolic (Ees), and ventricular diastolic (Ed) elastance (stiffness) may contribute to the pathogenesis of heart failure (HF) with preserved ejection fraction (HFnlEF). The prevalence of HFnlEF increases strikingly with age, particularly in women. We hypothesized that ventricular-vascular stiffening may occur with age and be more pronounced in women in the general community. Methods and Results— In a cross-sectional sample of Olmsted County, Minn, residents ≥45 years old (n=2042), clinical data, Doppler echocardiography, and blood pressure (BP) measurements were obtained. Ea was calculated from stroke volume and systolic BP and indexed to body size (EaI). Ees was calculated by a modified single-beat method using systolic and diastolic BP, stroke volume, ejection fraction, timing intervals, and an estimated normalized ventricular elastance at arterial end diastole. Operant Ed was calculated from Doppler indices reflective of atrial pressures and the diastolic filling volume. EaI, Ees, and Ed all increased with age in men and in women ( P <0.0001 for all). Ees increased more steeply with age in women ( P =0.002). Adjusted for age, EaI, Ees, and Ed were higher in women than in men ( P <0.0001 for all). Findings were similar in those without known or suspected cardiovascular disease (n=623). Conclusions— In the community, advancing age and female gender are associated with increases in vascular and ventricular systolic and diastolic stiffness even in the absence of cardiovascular disease. We speculate that this combined ventricular-vascular stiffening may contribute to the increased prevalence of HFnlEF in elderly persons and particularly in elderly women.